Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.

Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.

GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.

5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.

CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.

Some newly made compounds can block an enzyme linked to hair loss and prostate growth, with one in particular being very selective.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Finasteride is a medicine used to treat enlarged prostate and prostate cancer, and it works by changing how testosterone works in the body.

Finasteride reduces DHT to treat prostate issues and hair loss.

The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.

Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

MK-386 lowers DHT in blood and skin but not in semen.

PPCM microspheres can effectively release finasteride over 42 days.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

The new method for making Finasteride is cheaper and safer for large-scale production.

A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.

Finasteride treats baldness but may cause lasting sexual side effects.

Targeting FGF5 could help treat prostate cancer.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.